Nile Therapeutics appoints Darlene Horton as CMO
Nile Therapeutics, a San Mateo, Calif.-based biopharmaceutical company that develops novel therapeutics for heart failure patients, has appointed Darlene Horton, M.D. as its chief medical officer.
Horton was previously served as CMO of Itero Biopharmaceuticals, a venture-backed company that developed and out-licensed a biosimilar protein therapeutic. Prio to Itero, she served as senior vice president of clinical research at Scios, a Johnson & Johnson company. During Horton’s 12 year tenure at Scios, she was the clinical lead for Natrecor, a commercial product indicated for the treatment of acute heart failure. Following the acquisition of Scios by J&J, Horton also served as the head of the Cardiovascular Therapeutic Area Center of Excellence for all of J&J pharmaceutical companies.